Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors-Reference-Cited by-同舟云学术

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors

Published:2021-01-07 Issue:2 Volume:23 Page:
ISSN:1523-3790
Container-title:Current Oncology Reports
language:en
Short-container-title:Curr Oncol Rep

Author:

Pirozzi Flora,Poto Remo,Aran Luisa,Cuomo Alessandra,Galdiero Maria Rosaria,Spadaro Giuseppe,Abete Pasquale,Bonaduce Domenico,Marone Gianni,Tocchetti Carlo Gabriele^ORCID,Varricchi Gilda,Mercurio Valentina

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11912-020-01002-w.pdf

Reference64 articles.

1. Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14:73.

2. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161:205–14.

3. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy—revisited. Nat Rev Drug Discov. 2011;10:591–600.

4. Tocchetti CG, Ameri P, de Boer RA, D’Alessandra Y, Russo M, Sorriento D, et al. Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs. Novel cardio-oncology insights from the joint 2019 meeting of the ESC working groups of myocardial function and cellular biology of the heart. Cardiovasc Res. 2020;116(11):1820–1834. https://doi.org/10.1093/cvr/cvaa222.

5. •• Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019;115:854–68 State-of-the-art paper on the cardiovascular science science behind immunotherapy toxicsities.

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic factors in the pathogenesis of cardio-oncology;Journal of Translational Medicine;2024-08-05

2. Cardiovascular toxicities of immune therapies for cancer – a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio‐Oncology;European Journal of Heart Failure;2024-08

3. Sequential severe immune-related adverse events induced by PD-1 inhibitor: a case report and literature review;Frontiers in Oncology;2024-07-29

4. Nano revolution in cardiovascular health: Nanoparticles (NPs) as tiny titans for diagnosis and therapeutics;Current Problems in Cardiology;2024-05

5. Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology;Genes & Diseases;2024-03